Comparison · NCT00611130-e3bceb7d
CPP-109 Vigabatrin Tablets, 500 mg vs Matching Placebo Tablets: Proportion of Subjects in Each Treatment Group Abstinent During the Last 2 Weeks of Treatment.
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. CPP-109 Vigabatrin Tablets, 500 mg vs Matching Placebo Tablets: Proportion of Subjects in Each Treatment Group Abstinent During the Last 2 Weeks of Treatment. Trial comparisons, record NCT00611130-e3bceb7d. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00611130-e3bceb7d
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0761 | 0.0373 | 0.149 | wilson | |
| Risk in group 2 | 0.0532 | 0.0229 | 0.119 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0229 | -0.0531 | 0.102 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.43 | 0.471 | 4.35 | log | |
| Odds ratio, group 1 over group 2 | 1.47 | 0.448 | 4.8 | log | |
| Number needed to treat, for one more participant with the outcome on CPP-109 Vigabatrin Tablets, 500 mg than on Matching Placebo Tablets | 43.7 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | CPP-109 Vigabatrin Tablets, 500 mg | Vigabatrin Tablets, 1.5 g bid po, 12 weeks, computerized cognitive behavioral therapy plus contingency management.Subjects proceeded to a 12 week Treatment Phase, including a 2 week dose escalation period, a 9 week maintenance period (3.0 gm/day of vigabatrin) and a 1 week medication taper period. Finally, subjects then proceeded to a 12 week follow-up period. Subjects attended clinic visits 3 times per week (typically on Monday, Wednesday, and Friday) for efficacy and safety assessments and for treatment during the Screening/Baseline Phase and the 12 week Treatment Phase. Subjects returned for follow up visits at Weeks 13, 16, 20 and 24. | 7 | 92 | OG000 |
| Group 2 | Matching Placebo Tablets | Subjects proceeded to a 12 week Treatment Phase,receiving 3 tablets bid po Finally, subjects then proceeded to a 12 week follow-up period. Subjects attended clinic visits 3 times per week (typically on Monday, Wednesday, and Friday) during the Screening/Baseline Phase and the 12 week Treatment Phase. Subjects returned for follow up visits at Weeks 13, 16, 20 and 24. | 5 | 94 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Proportion of Subjects in Each Treatment Group Abstinent During the Last 2 Weeks of Treatment.
- Description
- Number of subjects in the CPP-109 Vigabatrin Group vs. Number in Placebo Group abstinent from using cocaine during Weeks 11 and 12 of the Treatment Phase.
- Time frame
- Week 13
- Population
- intent-to-treat
Source ClinicalTrials.gov
Trial
- Title
- Vigabatrin for Treatment of Cocaine Dependence
- NCT number
- NCT00611130
- Phases
- PHASE2
- Conditions
- Cocaine Dependence
- Interventions
- vigabatrin, placebo
- Lead sponsor
- Catalyst Pharmaceuticals, Inc.
- Results first posted
- 2012-06-12
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00611130?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00611130-e3bceb7d